Sponsor hub

University of California, San Francisco clinical trial failures

Review 119 stopped clinical trials from University of California, San Francisco, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 6 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials119
Likely biological signals6
Shown below100

Dominant stop reasons

OPERATIONAL
71
OTHER/UNKNOWN
41
EFFICACY/FUTILITY
4
SAFETY
2
REGULATORY
1

Notable sponsors

University of California, San Francisco
119

Related phases

Phase II
49
Phase IV
30
Phase I
28
Unknown
7
Phase III
4

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04940013: Missed Period Pill Study

Phase IV Menstrual Regulation trial by University of California, San Francisco. Stop reason: OPERATIONAL.

Lack of successful recruitment and loss of funding

NCT05288023: Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

Phase IV Resistance Bacterial trial by University of California, San Francisco. Stop reason: OTHER/UNKNOWN.

AVENIR I demonstrated efficacy of azithromycin MDA targeted to children 1-59 over 1-11 months in July 2023, thus this trial was stopped before outcomes were collected so Niger could expand the program nationally to include children 1-59 months.

NCT00133679: Chronic Sildenafil for Severe Diaphragmatic Hernia

Phase IV Hernia, Diaphragmatic trial by University of California, San Francisco. Stop reason: OTHER/UNKNOWN.

Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with possibility of placebo beyond 6 weeks of age on study protocol

NCT02605824: Clinical Trial of NAC in Asthma

Phase IV Asthma trial by University of California, San Francisco. Stop reason: OTHER/UNKNOWN.

The study was closed after we determined that this albuterol/NAC regimen may be associated with excessive bronchoconstriction.